Raymond James & Associates’s Usana Health Sciences USNA Stock Holding History

Raymond James & Associates’s Portfolio USNA Stock Details USNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-5,971	Closed	-$383K	–	3491
2017 Q2	$383K	Buy	5,971 +1,086	+22%	+$66.9K	﹤0.01%	2572
2017 Q1	$281K	Buy	+4,885	New	+$292K	﹤0.01%	2728
2014 Q4	–	Sell	-74,002	Closed	-$2.73M	–	2306
2014 Q3	$2.73M	Buy	74,002 +718	+1%	+$25.9K	0.02%	932
2014 Q2	$2.86M	Buy	73,284 +4,272	+6%	+$159K	0.02%	900
2014 Q1	$2.6M	Buy	+69,012	New	+$2.41M	0.02%	878

Other funds holding USNA

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

JIM

Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James & Associates's USNA Position: Q3 2017 in Review

Raymond James & Associates sold out of Usana Health Sciences (USNA) in Q3 2017, closing a stake of 5,971 shares — an estimated $383K sold.

Raymond James & Associates first reported a position in USNA in Q1 2014 and held it in 5 quarters. The position peaked at $2.86M in Q2 2014. 144 funds tracked by Wall St. Rank hold USNA as of Q3 2017.

Raymond James & Associates reported no remaining Usana Health Sciences position as of Q3 2017 after selling out during the quarter.
Raymond James & Associates sold 5,971 Usana Health Sciences shares in Q3 2017, an estimated $383K.
Raymond James & Associates first reported a position in Usana Health Sciences in Q1 2014 and held it in 5 quarters.
Raymond James & Associates's Usana Health Sciences position peaked at $2.86M in Q2 2014.
144 funds tracked by Wall St. Rank held Usana Health Sciences as of Q3 2017.

Based on Raymond James & Associates's 13F filing for Q3 2017, filed 13 Nov 2017.